Join our daily newsletter At The Bell to receive exclusive market insights
- Reproduction biotechnology and bio-separations company Memphasys (MEM) completes the maiden sale of Felix
- The sale was made to Diagens Biotechnology, which is a Chinese company that manufacturers and distributes human reproduction products across China
- This represents a major milestone for Memphasys as it increases its exposure to the Chinese market, which is the largest IVF market in the world
- Felix is Memphasys’ novel device that quickly and gently separates high-quality sperm from a sample for use in IVF procedures
- Memphasys was up 14.3 per cent on the market with shares trading at 12 cents
Reproduction biotechnology and bio-separations company Memphasys (MEM) has completed the maiden sale of Felix.
The sale was made to Diagens Biotechnology, which is a Chinese company that manufactures and distributes human reproduction products across China.
This maiden order is valued at $11,000 and comprises a console and a starter kit of cartridges.
This represents a major milestone for Memphasys as it increases its exposure to the Chinese market, which is the largest IVF market in the world.
Felix is Memphasys’ novel device that quickly and gently separates high-quality sperm from a sample for use in IVF procedures.
While it is initially for use in human IVF processes, it will later be applied for use in animal artificial reproduction.
Felix was developed with global reproductive medicine expert, Professor John Aitken at the University of Newcastle.
Memphasys’ earlier prototype device, the CS10, was proven to work and led to some live human births in previously infertile couples, however, it needed substantial change to be suitable for use in IVF clinics.
Further, Memphasys remains in regular contact with its partners to accelerate the commercialisation of Felix. The company is aiming to execute its first clinical sales in Q4 2021.
Memphasys was up 14.3 per cent on the market, with shares trading at 12 cents at 12:08 pm AEDT.
